Table 3.
Changes in COVID-19 symptoms before and after accessing the Korean Medicine telemedicine program.
COVID-19 symptoms and severity | At first call, n (%) | At last call, n (%) | P valuea | ||||
Headache | <.001 | ||||||
|
Severe | 3 (0.1) | 0 (0.0) | N/Ab | |||
|
Moderate | 49 (2.4) | 3 (0.2) | N/A | |||
|
Mild | 361 (17.4) | 112 (9.3) | N/A | |||
|
None | 1658 (80.1) | 1092 (90.5) | N/A | |||
|
Total | 2071 (100.0) | 1207 (100.0) | N/A | |||
Chills | <.001 | ||||||
|
Severe | 2 (0.1) | 0 (0.0) | N/A | |||
|
Moderate | 11 (0.5) | 0 (0.0) | N/A | |||
|
Mild | 207 (10.0) | 57 (4.7) | N/A | |||
|
None | 1843 (89.3) | 1158 (95.3) | N/A | |||
|
Total | 2063 (100.0) | 1215 (100.0) | N/A | |||
Sputum | <.001 | ||||||
|
Severe | 12 (0.6) | 2 (0.2) | N/A | |||
|
Moderate | 43 (2.0) | 10 (0.8) | N/A | |||
|
Mild | 707 (33.4) | 308 (24.0) | N/A | |||
|
None | 1357 (64.0) | 963 (75.1) | N/A | |||
|
Total | 2119 (100.0) | 1283 (100.0) | N/A | |||
Dry cough | <.001 | ||||||
|
Severe | 3 (0.1) | 0 (0.0) | N/A | |||
|
Moderate | 116 (5.5) | 16 (1.3) | N/A | |||
|
Mild | 640 (30.6) | 233 (18.7) | N/A | |||
|
None | 1335 (63.8) | 994 (80.0) | N/A | |||
|
Total | 2094 (100.0) | 1243 (100.0) | N/A | |||
Sore throat | <.001 | ||||||
|
Severe | 2 (0.1) | 0 (0.0) | N/A | |||
|
Moderate | 43 (2.1) | 2 (0.2) | N/A | |||
|
Mild | 355 (17.0) | 117 (9.5) | N/A | |||
|
None | 1684 (80.8) | 1113 (90.3) | N/A | |||
|
Total | 2084 (100.0) | 1232 (100.0) | N/A | |||
Fatigue | <.001 | ||||||
|
Severe | 15 (0.7) | 3 (0.2) | N/A | |||
|
Moderate | 164 (8.1) | 27 (2.2) | N/A | |||
|
Mild | 616 (30.5) | 325 (26.7) | N/A | |||
|
None | 1223 (60.6) | 860 (70.8) | N/A | |||
|
Total | 2018 (100.0) | 1215 (100.0) | N/A | |||
Muscle pain | <.001 | ||||||
|
Severe | 7 (0.3) | 0 (0.0) | N/A | |||
|
Moderate | 60 (2.9) | 8 (0.7) | N/A | |||
|
Mild | 334 (16.2) | 108 (9.1) | N/A | |||
|
None | 1661 (80.6) | 1066 (90.2) | N/A | |||
|
Total | 2062 (100.0) | 1182 (100.0) | N/A | |||
Rhinorrhea | <.001 | ||||||
|
Severe | 9 (0.4) | 0 (0.0) | N/A | |||
|
Moderate | 43 (2.1) | 4 (0.3) | N/A | |||
|
Mild | 316 (15.3) | 164 (13.6) | N/A | |||
|
None | 1694 (82.2) | 1042 (86.1) | N/A | |||
|
Total | 2062 (100.0) | 1210 (100.0) | N/A | |||
Nasal congestion | <.001 | ||||||
|
Severe | 5 (0.2) | 1 (0.1) | N/A | |||
|
Moderate | 42 (2.0) | 4 (0.3) | N/A | |||
|
Mild | 386 (18.7) | 118 (9.8) | N/A | |||
|
None | 1627 (79.0) | 1078 (89.8) | N/A | |||
|
Total | 2060 (100.0) | 1201 (100.0) | N/A | |||
Dyspnea | <.001 | ||||||
|
Severe | 17 (0.9) | 0 (0.0) | N/A | |||
|
Moderate | 36 (1.9) | 8 (0.7) | N/A | |||
|
Mild | 413 (21.7) | 137 (12.8) | N/A | |||
|
None | 1439 (75.5) | 924 (86.4) | N/A | |||
|
Total | 1905 (100.0) | 1069 (100.0) | N/A | |||
Chest tightness | <.001 | ||||||
|
Severe | 0 (0.0) | 0 (0.0) | N/A | |||
|
Moderate | 51 (2.5) | 4 (0.3) | N/A | |||
|
Mild | 142 (7.0) | 29 (2.5) | N/A | |||
|
None | 1844 (90.5) | 1144 (97.2) | N/A | |||
|
Total | 2037 (100.0) | 1171 (100.0) | N/A | |||
Diarrhea | <.001 | ||||||
|
Severe | 6 (0.3) | 1 (0.1) | N/A | |||
|
Moderate | 13 (0.6) | 0 (0.0) | N/A | |||
|
Mild | 181 (8.8) | 87 (7.4) | N/A | |||
|
None | 1853 (90.3) | 1095 (92.6) | N/A | |||
|
Total | 2053 (100.0) | 1183 (100.0) | N/A | |||
Loss of appetite | <.001 | ||||||
|
Severe | 10 (0.5) | 2 (0.2) | N/A | |||
|
Moderate | 134 (6.7) | 25 (2.1) | N/A | |||
|
Mild | 449 (22.5) | 154 (12.9) | N/A | |||
|
None | 1407 (70.4) | 1009 (84.8) | N/A | |||
|
Total | 2000 (100.0) | 1190 (100.0) | N/A |
aThe Wilcoxon signed-rank test was performed.
bN/A: not applicable.